MammoScreen
DeviceDiagnostic reading aid for breast cancer screening
NCT Number: NCT05800132
The goal of this clinical trial is to compare, for the second reading of screening mammograms, the standard of care with an AI assisted scenario.
The main questions it aims to answer are:
* will the experimental pathway be non-inferior to the standard pathway? * will the experimental pathway be economically superior to the standard pathway?
Participants will receive screening mammograms, as part of the breast cancer screening program. Researchers will compare the interpretation made by the second reader in the standard pathway with the AI assisted interpretation made by a different reader in the experimental pathway.
Interested in participating?
Request Info50 year–74 year
Female
Interventional
Not applicable
Centre de radiologie Les Défensions, Aubagne, France
All mammograms eligible for a second reading, and included in the study, go through 2 arms:
The most pejorative assessment among the two arms is used as the final decision: if both arms consider the mammogram as negative, the participant won't be recalled, if one arm consider the mammogram as positive, the participant will be called back for further examinations.
Clinical performances and economical impacts of both scenarii will be compared.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Diagnostic reading aid for breast cancer screening
Time frame: End of the inclusion period 24 months
Number of patients that are called back for further examinations divided by the total number of patient receiving a second reading.
Time frame: End of the inclusion period 24 months
Number of biopsy proven cancers divided by the total number of patient receiving a second reading
Time frame: End of the follow_up period 48 months
True and false-positive rate
Time frame: End of the follow_up period 48 months
Difference in direct medical costs between the two arms Difference in annual budgetary impact on the French National Health Insurance between the two arms
Time frame: End of the inclusion period 24 months
Time period [in days] between the day of the screening and the access to results
Time frame: End of the inclusion period 24 months
Time needed [in seconds] to interpret a mammogram
Contact information is provided by the study sponsor or research team.
Brigitte Seradour
CONTACT
Patrice Heid
CONTACT
Therapixel
Industry
Évaluation de la Performance Diagnostique du dépistage du Cancer du Sein, Pour Une Seconde Lecture Des clichés de Mammographie assistée du Dispositif médical à Base d'Intelligence Artificielle MammoScreen
Acronym: IMA-L2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04816006
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Phoenix, Arizona, United States
View Trial DetailsNCT05625659
Breast Cancer, Breast Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT06954337
Breast Cancer, Breast Diseases
Basking Ridge, New Jersey, United States
View Trial DetailsNCT07340541
Breast Cancer, Breast Diseases
Baltimore, Maryland, United States
View Trial Details